Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VOR	$23.09	-2.47%	393.46K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VOR	$23.09	-2.5%	393.46K
3
4
5
6

VOR

VOR

Get Vor Biopharma Inc. Data in Excel

Get Vor Biopharma Inc. Data in Excel